“…The financial impact of health policies, especially with regard to prevention, of the treatment of installed thromboembolic event and the cost of medications must be considered, as the use of THA has increased in the world population. 18 One must emphasize that the effectiveness of these measures varies according to the patient's profile, surgical technique used, operative time, 16 patient compliance, 19 as well as their clinical evaluation, since the use of ENX causes laboratory alterations in liver function, in DHL, in 53% of the cases, albeit without clinical repercussions. 20 Thus, an effective measure in preventing VTE and reducing hospital time, in addition to reducing other adverse events, is the early The contraindication for the use of pharmacological methods was: active bleeding or active peptic ulcer, use of anticoagulation, heparin allergy or thrombocytopenia, coagulopathy (thrombocytopenia < 100,000/mm³ or NR°> 1.5), uncontrolled systemic arterial hypertension (> 180 × 110 mmHg), persistent renal failure (clearance < 30 ml/min), recent intracranial or ocular surgery < 2weeks, CSF collection in the last 24 hours.…”